Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287877076> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4287877076 endingPage "334" @default.
- W4287877076 startingPage "329" @default.
- W4287877076 abstract "Objective To review the data informing the US Food and Drug Administration (FDA) approval for aducanumab for mild cognitive impairment (MCI) and mild Alzheimer's disease (AD). Data Sources At the time of writing there were no peer-reviewed published studies on aducanumab. All data presented are derived directly from the material Biogen submitted to the FDA for approval. The three studies that will be reviewed are: Multiple Dose Study of Aducanumab in Participants With Prodromal or Mild AD (PRIME), 221AD302 Phase 3 Study of Aducanumab in Early AD (EMERGE), 221AD301 Phase 3 Study of Aducanumab in Early AD (ENGAGE). Data Synthesis PRIME, which was a phase 1 study, demonstrated the most common adverse drug reactions were amyloid-related imaging abnormalities (ARIA), which occurred at rates up to 47% (10 mg/kg group), headache (25%), urinary tract infection (16%), and upper respiratory tract infection (19%). EMERGE demonstrated that high-dose aducanumab was clinically significant at slowing down clinical decline. However, ENGAGE was terminated early based on a futility analysis. Prior to termination ENGAGE demonstrated no clinical difference between treatment and placebo regarding the primary endpoint of slowing clinical decline. Conclusion Based on the data to date, it is difficult to accurately assess the role of aducanumab in patients with MCI or mild AD. EMERGE showed benefit with high-dose aducanumab slowing clinical decline. However, ENGAGE did not duplicate this benefit. With conflicting evidence of positive outcomes, future phase III studies are needed to confirm efficacy." @default.
- W4287877076 created "2022-07-26" @default.
- W4287877076 creator A5017918198 @default.
- W4287877076 creator A5054387459 @default.
- W4287877076 creator A5058539708 @default.
- W4287877076 date "2022-08-01" @default.
- W4287877076 modified "2023-10-16" @default.
- W4287877076 title "Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies" @default.
- W4287877076 cites W1855997172 @default.
- W4287877076 cites W1995360192 @default.
- W4287877076 cites W2582073057 @default.
- W4287877076 cites W3097527510 @default.
- W4287877076 cites W3134488059 @default.
- W4287877076 cites W3211883810 @default.
- W4287877076 cites W4251986800 @default.
- W4287877076 cites W4378711534 @default.
- W4287877076 doi "https://doi.org/10.4140/tcp.n.2022.329" @default.
- W4287877076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35879846" @default.
- W4287877076 hasPublicationYear "2022" @default.
- W4287877076 type Work @default.
- W4287877076 citedByCount "7" @default.
- W4287877076 countsByYear W42878770762022 @default.
- W4287877076 countsByYear W42878770762023 @default.
- W4287877076 crossrefType "journal-article" @default.
- W4287877076 hasAuthorship W4287877076A5017918198 @default.
- W4287877076 hasAuthorship W4287877076A5054387459 @default.
- W4287877076 hasAuthorship W4287877076A5058539708 @default.
- W4287877076 hasConcept C126322002 @default.
- W4287877076 hasConcept C142724271 @default.
- W4287877076 hasConcept C187212893 @default.
- W4287877076 hasConcept C197934379 @default.
- W4287877076 hasConcept C203092338 @default.
- W4287877076 hasConcept C204787440 @default.
- W4287877076 hasConcept C27081682 @default.
- W4287877076 hasConcept C2779134260 @default.
- W4287877076 hasConcept C2984915365 @default.
- W4287877076 hasConcept C535046627 @default.
- W4287877076 hasConcept C71924100 @default.
- W4287877076 hasConceptScore W4287877076C126322002 @default.
- W4287877076 hasConceptScore W4287877076C142724271 @default.
- W4287877076 hasConceptScore W4287877076C187212893 @default.
- W4287877076 hasConceptScore W4287877076C197934379 @default.
- W4287877076 hasConceptScore W4287877076C203092338 @default.
- W4287877076 hasConceptScore W4287877076C204787440 @default.
- W4287877076 hasConceptScore W4287877076C27081682 @default.
- W4287877076 hasConceptScore W4287877076C2779134260 @default.
- W4287877076 hasConceptScore W4287877076C2984915365 @default.
- W4287877076 hasConceptScore W4287877076C535046627 @default.
- W4287877076 hasConceptScore W4287877076C71924100 @default.
- W4287877076 hasIssue "8" @default.
- W4287877076 hasLocation W42878770761 @default.
- W4287877076 hasLocation W42878770762 @default.
- W4287877076 hasOpenAccess W4287877076 @default.
- W4287877076 hasPrimaryLocation W42878770761 @default.
- W4287877076 hasRelatedWork W1859326399 @default.
- W4287877076 hasRelatedWork W1966127473 @default.
- W4287877076 hasRelatedWork W1974781192 @default.
- W4287877076 hasRelatedWork W1992458659 @default.
- W4287877076 hasRelatedWork W2074965717 @default.
- W4287877076 hasRelatedWork W2085249681 @default.
- W4287877076 hasRelatedWork W2085650940 @default.
- W4287877076 hasRelatedWork W2085830368 @default.
- W4287877076 hasRelatedWork W2119160676 @default.
- W4287877076 hasRelatedWork W2130961106 @default.
- W4287877076 hasVolume "37" @default.
- W4287877076 isParatext "false" @default.
- W4287877076 isRetracted "false" @default.
- W4287877076 workType "article" @default.